AEON
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in Newport Beach, California.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.97 | $0 | -$3M |
| 2025 Q4 | -3.07 | $0 | -$5M |
| 2025 Q3 | -0.39 | $0 | -$3M |
| 2025 Q2 | -0.60 | $0 | -$2M |
| 2025 Q1 | 2.28 | $0 | -$8M |
| 2024 Q4 | 3.76 | $0 | -$621,000 |
| 2024 Q3 |
| -11.53 |
| $0 |
| -$3M |
| 2024 Q2 | 304.00 | $0 | -$8M |